Navigation Links
Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of,Docetaxel Chemotherapy

VIENNA, Austria, May 23, 2007-The chemotherapy drug docetaxel currently offers the best treatment for androgen-independent prostate cancer. That is the result of a now published clinical trial that compared the efficacy of the two most widely used chemotherapy drugs. When using docetaxel, the risk of disease progression was cut by more than 50% than when using the next-best chemotherapy drug.

The use of chemotherapy to treat prostate cancer has rapidly grown in importance over recent years, with several comprehensive clinical trials helping to drive forward progress. In two of these trials, the chemotherapy drug docetaxel offered patients a significantly improved prognosis. However, other clinical trials indicated that the drug vinorelbine, which like docetaxel acts on cellular microtubuli, also produces impressive results and it is often used as an alternative to docetaxel.

The Medical University of Vienna has now carried out the world¹s first direct comparison of both drugs, giving doctors valuable support in choosing the appropriate treatment for their patients.

TWO DRUGS ­ ONE CLEAR RESULT The trial clearly demonstrated the superior efficacy of docetaxel by using 40 patients to directly compare the drug against vinorelbine. The initiator and coordinator of the study, Prof. Michael Krainer, oncologist at the Department of Internal Medicine I, Medical University of Vienna, describes the outcome of the trial: "The median time to disease progression in all 20 patients we treated with docetaxel was more than three times longer than in the patients given vinorelbine." Cancerous tumours in patients from the first group did not progress for an average period of 14.5 months. In contrast, the median time to first disease progression in the patients treated with vinorelbine was only 4.4 months.

Values for "prostate-specific antigen" (PSA), an established tumour marker that indicate s when a cancer is progressing, were similarly conclusive. While 62.5% of the patients treated with docetaxel exhibited an over 50% reduction in PSA, a reduction of only 11.1% was detected among those treated with vinorelbine. This is a clear indication that docetaxel restricts tumour growth.

Even the team working on the study were surprised at the scale of the reduction in PSA produced by docetaxel. Prof. Krainer explains: "We used a much lower dose than that used during the TAX 327 study, which was the first to demonstrate the efficacy of docetaxel in a phase III trial, and we also chose not to boost the efficacy of the chemotherapy drug with cortisone premedication. Nevertheless, we still achieved a similar effect on PSA." Prof. Krainer believes this effect could be due to the lower toxicity which was produced by using a lower dose and which helped improve the efficacy of the therapy regimen.

Cancer specialist Dr. William K. Oh from the Dana-Farber Cancer Institute at Harvard Medical School also highlights this finding in his editorial comment attached to the publication. In his opinion, the therapy regimen used in Vienna offers a good alternative for patients in whom steroids are contraindicated. He also points out that the study demonstrated a 28.6% reduction of PSA in patients who had stopped responding to docetaxel and were instead using vinorelbine as second line chemotherapy, indicating that this drug will continue to play an important role in cancer treatment.

SMALL STUDY ­ BIG ISSUE This open-label, randomized phase II trial involved a total of 40 chemotherapy-naïve patients with histologically proven androgen-independent prostate cancer. The patients were divided into two groups that were given 25mg/m2 weekly doses of docetaxel or vinorelbine. Referring to the scope of the trial, Prof. Krainer states: "Of course, smaller studies such as this phase II trial cannot produce definitive conclusions. These can only be generated by major phase III trials conducted at several centres. However, it is extremely important to establish in advance which of the treatments currently in use should be tested in such large-scale and expensive trials. Our impressive findings on docetaxel provide clear data for making this decision.²

Original publication: A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients with Androgen Independent Prostate Cancer. J. Urol., DOI:10-1016/j.juro.2007.01.148 Available to download at: Scientific contact: Prof. Michael Krainer Medical University of Vienna 1090 Vienna, Austria T +43 / 664 / 183 76 77 E

Copy Editing and Distribution: PR&D - Public Relations for Research & Development Campus Vienna Biocenter 2 1030 Vienna, Austria T +43 / 1 / 505 70 44 E

Michaela Fritsch Assistentin

PR&D - Public Relations for Research & Development

T +43 1 505 70 44 F +43 1 505 50 83 E

Campus Vienna Biocenter 2 A 1030 Vienna, Austria


Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
5. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
6. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
7. Quest PharmaTechs Prostate Cancer Program Update
8. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
9. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer
Post Your Comments:
(Date:11/25/2015)... Nov. 26, 2015  The total global healthcare industry is ... 2015-2016. Latin America has the highest ... (excluding Japan ), is second with growth ... to face increased healthcare expenditure. In 2013-2014, total government funded ... 43.5% in 2008-2009 to 41.2% in 2013-2014. In real terms, ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... The print component of “Supporting Our Caregivers” ... New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies and ... vast social media strategy and across a network of top news sites and ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A simply ... Jones, is an interesting show that delves into an array of issues that are ... that could benefit from open dialogue, this show is changing the subjects consumers focus ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge ... imaging in the Waterloo region. Using the Ocean Platform, family physicians can now ... their electronic medical record (EMR) without the need for redundant patient entry or ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... opinion process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits ... place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held ...
Breaking Medicine News(10 mins):